Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 26 of 65 · 3108 articles
Researchers are exploring ways to improve cell therapies for IBD by making therapeutic cells produce anti-inflammatory molecules like IL-10. If scalable and safe, non-viral engineering of MSCs could lead to...
New colon-targeted formulations aim to concentrate treatment where inflammation is in ulcerative colitis, which could increase benefit and reduce systemic side effects. Formulation research like this is an early step...
The work links climate and sociodemographic context to IBD burden in tropical regions, which can influence diagnostic recognition, resource needs, and research priorities for communities where IBD is rising.
People with IBD commonly experience anxiety, depression, and other neurological symptoms. Understanding gut–brain axis mechanisms may help explain these comorbidities and point to future treatments.
Automated, quantitative analysis of pathology slides could reduce variability in histological scoring and help track histological healing — a growing therapeutic target in ulcerative colitis.
Patients with CGD can develop an IBD-like condition that is hard to treat because many immunosuppressive drugs raise infection risk. This trial suggests thalidomide may reduce intestinal inflammation in CGD-IBD without...
This project tests whether common nanoplastics that people ingest could damage the gut barrier, alter gut microbes’ estrogen metabolism, and injure enteric nerves — processes that might increase risk or severity of IBD.
Piezo channels appear central to how mechanical signals influence the gut barrier, immunity, and secretion — processes that can affect inflammation and symptoms in IBD, IBS, and colon cancer. Understanding them could...
This study links genetic variation in fatty-acid–desaturase genes with membrane PUFA profiles and inflammatory markers in Crohn’s disease. If replicated, erythrocyte desaturase indices could become integrative biomarkers...
Antibiotic use patterns in hospitalized IBD patients affect infection risks, microbiome impact, resistance pressure, length of stay, and costs. Shifting focus from simple exposure counts to intensity and escalation can...
A controlled trial found low-dose naltrexone did not induce endoscopic or clinical remission in Crohn's disease, but it showed a possible benefit for reducing fatigue. Patients seeking symptom relief without...
Researchers are studying a parasite-derived protein (Fh15) that may reduce neutrophil-driven inflammation in sepsis and ulcerative colitis models; this could point toward new anti-inflammatory drug approaches in the...
Researchers are investigating fungal contributions to IBD-related gut inflammation; understanding fungal persistence mechanisms could eventually inform therapies or diagnostics for dysbiosis-associated worsening of...
Researchers found that nearly all people with UC have high-titer autoantibodies to the epithelial integrin αvβ6 that can precede disease and associate with worse outcomes. Understanding whether and how these antibodies...
This project explores a specific molecular pathway (WNT2B → NF-κB/IL‑6) that may protect the colon from inflammation. If validated, it could identify a new therapeutic target for IBD and help explain why some people...
The study targets REV-ERBα, a regulator of TH17 cells that contribute to Crohn’s disease and ulcerative colitis, so its findings could identify new molecular pathways to target for IBD therapies.
Researchers aim to build and study tiny gut phages (Microviridae) that are largely known only from DNA sequences. Learning how these phages shape microbial communities could help explain virome-linked changes seen in...
Researchers are exploring whether vagus nerve stimulation or drugs targeting the α7 nicotinic receptor could reduce liver inflammation from heavy alcohol use. If mechanisms are confirmed, this could point to new...
This project aims to map microbe-specific T cells in Crohn's disease using single-cell RNA and TCR sequencing. Findings could reveal antigen-specific mechanisms driving IBD and help lay groundwork for targeted...
The project targets patients with refractory IBD who lack effective options; a new allogeneic stromal cell therapy could expand treatment choices for people who fail multiple drugs. The work focuses on immune pathways...
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...
This project aims to understand how gut-adapted eosinophils support immune homeostasis or drive pathology in conditions that include IBD and eosinophilic GI disorders, with the goal of enabling more precise...
Pregnant people with IBD or other autoimmune diseases often face tough choices about continuing biologics or JAK inhibitors. CARE-HP aims to produce broader, disease-specific evidence to help patients and clinicians...
If intestinal stem cells retain an inflammatory “memory,” that could help explain why some people with IBD have persistent barrier problems and repeated flares despite therapy. Discovering durable molecular changes in...
This project aims to develop a new anti-inflammatory therapy targeting TREM-1 on macrophages, a pathway implicated in IBD. If successful, the approach could offer an alternative for patients who do not respond to current...
This research highlights a new metabolic pathway that helps protect the intestinal lining in IBD by preventing ferroptosis, a form of cell death linked to barrier breakdown.
A quantitative, biopsy-based measure of collagen architecture could help study intestinal fibrosis, which underlies stricture formation in Crohn’s disease. Feasibility data support further validation work that may lead...
Barrier dysfunction is central to IBD pathogenesis; a compound that restores tight junctions and reduces permeability in preclinical models could eventually lead to new therapies that protect the gut lining and reduce...
Oral and upper-GI involvement in Crohn's can be missed and may change how disease is diagnosed and managed. A focused review helps clinicians and researchers spot gaps in diagnostics and treatment research.
Many people with IBD also have overweight or obesity; GLP-1 receptor agonists are being used for weight loss and may affect inflammation and IBD outcomes. This review summarizes current evidence on safety, effectiveness,...
The microbiome is connected to IBD through effects on immune regulation and barrier function; advances in understanding could inform future microbiome-directed therapies that matter to people with IBD.
A new single-cell analysis tool may help researchers and clinicians studying IBD (here shown for ulcerative colitis) to detect and interpret changes in cell–cell signaling that accompany disease or treatment response.
Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.
People with IBD often need biologic therapy during their reproductive years. This review compiles comparative evidence about pregnancy risks with different biologics to inform decisions about continuing or switching...
This study reports a non-invasive fluorescence probe that detects a reactive nitrogen species (peroxynitrite) linked to intestinal inflammation and shows signal changes in cells, animal models, and mouse feces — a...
A potential link between ultra-processed food intake and Crohn’s relapse could influence dietary conversations for people in remission, but the current evidence is weak and not definitive.
Early-stage research suggests a specific probiotic strain may reduce inflammation and alter the gut microbiome and immune-related proteins in an animal model of ulcerative colitis, which could point to future therapeutic...
Genetic evidence for causal links between other diseases (for example asthma or multiple sclerosis) and IBD can help researchers prioritize biological pathways and potential therapeutic targets, and may explain why some...
A naturally occurring pigment (C3G) improved inflammation and barrier markers in a mouse colitis model, which could be of interest to people exploring nutrition-related ways to support gut health.
This study provides real‑world data on how long biologic‑experienced UC patients stay on ustekinumab, which helps patients and clinicians set expectations about drug persistence and factors that might influence stopping...
This study describes a new microbiome-engineering approach that reduced inflammation in mouse colitis models by sequestering cysteine and altering T cell behavior. If followed up, it could point to novel future therapies...
Fibrosis and stricture formation are important complications in Crohn’s disease; a biopsy-based, quantitative way to measure collagen architecture could help research into fibrotic disease mechanisms and eventually...
Pathological features of intestinal lesions help doctors and researchers understand disease progression, identify complications, and interpret biopsies. Improvements or corrections to such descriptions can affect how...
The study suggests that a simple, multidomain functional measure (intrinsic capacity) is linked to later IBD risk and that combining it with genetic risk may better identify people at higher risk—especially for Crohn’s...
PFAS exposure is widespread; if PFNA worsens intestinal inflammation through a defined immune pathway, it could help explain environmental contributions to IBD flares and point to new research targets for mitigation.
This preclinical study suggests a heat‑killed form of Lactobacillus acidophilus LA‑5 reduced inflammation, oxidative stress, and markers of regulated cell death in a mouse model of ulcerative colitis — with effects...
Cure8 found this source from Journal of gastroenterology and hepatology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original...
